Globus Medical, Inc. Class A

Welcome to Globus Medical's second quarter 2025 earnings call. At this time, all lines will be on mute, and a question and answer session will be held after the prepared remarks. I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.

Thank you, Haley, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be David Paul, Globus founder and executive chairman. Keith Pfeil, President and Chief Executive Officer, and Kyle Klein, Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2024 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available in the schedules accompanying the press release and on the investor relations section of the Globus Medical website. With that, I'll turn the call over to David Paul, our founder and executive chairman.

Thank you, Brian, and good evening, everyone. I want to begin by congratulating Keith Feil on his promotion to the role as CEO of Globus Medical, effective July 18, 2025. Keith will lead Globus on setting and executing our strategy to become the preeminent musculoskeletal technology company in the world. Before joining Globus Medical, Keith built nearly two decades of experience in corporate finance, operations, and strategic leadership. He began his career in public accounting with Arthur Anderson, later transitioning to KPMG, where he was primarily focused on financial audits and compliance. Keith later moved into the consumer products industry, where he advanced through a series of finance and operational leadership roles including serving in a divisional CFO role for several years and ultimately serving as executive vice president and CFO. His tenure included extensive experience leading financial planning, M&A due diligence, investor relations, manufacturing and sourcing initiatives, as well as large-scale restructuring initiatives that improved liquidity and operational efficiencies. Beginning in 2019, when Keith started at Globus as our CFO, it was obvious to me and our board that he was destined to one day be in this CEO role. We quickly began exposing him to all aspects of our business over the last six years. In addition to finance, Keith was given responsibility within the company in IT, operations, pricing, regulatory, quality, and commercial. Finally, Keith led the financial due diligence and the entire integration planning effort for Nuvesiv and Nevro, and has made amazing progress in a short period of time with both. Keith has become an integral part of the Globus executive team, providing steady, positive, and committed leadership that will now extend to the entire organization to drive our strategic goals. I also want to take this opportunity to thank Dan Scavilla for his many contributions to Globus over the last 10 years. He has been a great partner to Globus and me and has served with distinction for the last 10 years, beginning with his role as CFO and his last three years as CEO. We wish Dan well in his new position at Dentsply. I will now turn the call over to Keith and Kyle for their comments on our quarter and will have a few words to say in closing at the end.